NM23 Protein as a Target for Blood Cancer Treatment
Author Information
Author(s): Junko Okabe-Kado, Takashi Kasukabe, Yasuhiko Kaneko
Primary Institution: Research Institute for Clinical Oncology, Saitama Cancer Center
Hypothesis
Does the extracellular NM23-H1 protein play a role in the prognosis and treatment of hematologic malignancies?
Conclusion
Elevated serum levels of NM23-H1 protein are associated with poor prognosis in patients with hematologic malignancies.
Supporting Evidence
- Patients with high NM23-H1 levels had a 0% survival rate within 2 years.
- The study found that elevated NM23-H1 levels significantly contributed to poor prognosis in AML patients.
- High NM23-H1 levels were also linked to poor outcomes in aggressive non-Hodgkin's lymphoma.
Takeaway
High levels of a protein called NM23-H1 in the blood can make leukemia patients sicker, but it might also be a target for new treatments.
Methodology
The study measured serum NM23-H1 levels in patients and analyzed their association with clinical outcomes.
Potential Biases
Potential biases in patient selection and measurement of NM23-H1 levels.
Limitations
The study may not account for all variables affecting patient prognosis.
Participant Demographics
102 patients with acute myelogenous leukemia (AML) and various hematologic malignancies.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website